TX-ROKA
26.4.2018 20:17:07 CEST | Business Wire | Press release
ROKA , the Austin-based performance design company, has announced a multiyear eyewear partnership with eight-time triathlon world champion and Olympic silver medalist Javier Gómez Noya , expanding their existing relationship for technical race apparel and equipment. Starting in 2018, Gómez will train and race in ROKA’s eyewear, the lightest, most advanced performance optics in the world, in the pursuit of his first Ironman World Championship.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180426006510/en/
“I first tried the Advanced Performance eyewear while I was at ROKA’s headquarters in Texas, and right away I knew they were the glasses I should be using everyday,” Gómez Noya says. “There’s nothing like them in terms of weight, retention, and quality of vision. Whether cycling or running, you can’t feel that you’re wearing them but you have an incredible field of view.”
Gómez Noya began his partnership with ROKA four years ago, when he chose to compete in ROKA’s innovative line of wetsuits, swimskins, goggles, and triathlon race apparel. Over the past four years, Gómez Noya has worn ROKA to victory in three ITU World Triathlon Series titles, two IRONMAN 70.3 World Championships, and an Xterra Off-Road World Championship. Now he’ll be wearing ROKA optics as well as ROKA’s technical race and swim apparel as he attempts to win his first Ironman World Championship in Hawaii this year and cement his legacy as one of the greatest triathletes of all time.
"Javier has been with us every step of the way over the last four years, so we're thrilled to continue that partnership as we take on the challenge of creating the most advanced optics the world has ever seen," says ROKA CEO and Co-Founder, Rob Canales. "Having the input of an athlete of Javier's caliber is critical to the innovation and development of our products. That now includes our latest Maverick X wetsuit , our technical race apparel, and our advanced optics. We look forward to expanding our work with him to redefine standards in the performance eyewear market. It's about pushing limits, and nobody does that better than Javier.”
Gómez Noya will train and race in ROKA’s recently released Advanced Performance sunglasses, designed from scratch to be the lightest, highest performing, and most comfortable eyewear in the world, with unmatched field of vision and fit. “ROKA’s technical apparel and goggles have been a secret weapon for most of my world championships, and now I’m thrilled to have that same world-beating standard for my eyewear as I take on this new challenge of becoming Ironman World Champion,” Gómez Noya says. “My relationship with ROKA is about working together to make something better, and I’m confident that I now have the best eyewear team in the world in my corner for this next phase of my career.”
ROKA’s Advanced Performance eyewear is available in five styles and up to ten different lens tint options, giving athletes the ability to completely customize their eyewear to fit their specific needs. The unique design is the culmination of years of R&D by ROKA’s world-class team of designers and engineers. Weighing between 21 – 25 grams, the collection has set a new standard in the performance optics market that has to be felt to be believed.
Visit www.roka.com or email sales@roka.com to learn more about the company’s growing lines of premium performance eyewear, apparel, and equipment. Follow ROKA on social media at Facebook , Twitter , and Instagram .
About ROKA
ROKA started in a garage in Austin, Texas with humble beginnings and laser-beam focus. Our mission is to unlock human potential. To equip, empower, inspire, and ignite. We serve those who seek to redefine the standard, to push themselves to the limit – whatever and wherever that may be. When we see an opportunity to innovate, to challenge the status quo, to disrupt a complacent or monopolistic market, we go all in.
Since launching in 2016, ROKA eyewear has been worn to victory by multiple world champions across a variety of sports and challenges, from the Dakar Rally in South America to the Winter Olympics in PyeongChang, South Korea. Gómez Noya is one of 40 elite athletes from all walks of sport who will use Advanced Performance eyewear in 2018, helping them test their limits under the most extreme conditions. For more information, visit www.roka.com/contact
View source version on businesswire.com: https://www.businesswire.com/news/home/20180426006510/en/
Contact:
Editorial contact
ROKA
Diane Thibert
VP Communications &
Public Relations
(310) 804-2400 / diane@roka.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vena Completes Acterys Acquisition to Accelerate Orchestrated Planning for the Microsoft Ecosystem26.3.2026 14:00:00 CET | Press release
The combination connects AI-driven financial and operational planning, analytics and execution across Microsoft Excel and Power BI, removing decision latency for Microsoft-centric enterprises. Vena, the AI-powered Orchestrated Performance Management platform purpose-built to fully amplify the Microsoft technology ecosystem, today announced it has completed its acquisition of Acterys, the leading Microsoft Power BI–based operational planning and app development platform. The move strengthens Vena’s Orchestrated Planning solution and begins phased integration of the two platforms. Modern enterprises are struggling to keep up with the volatility and dynamism of the markets they serve. Market drivers and signals shift rapidly, and the ability to assess, plan and execute with confidence and speed is more important than ever. These forces, combined with overwhelming data density and disparity, have created a new constraint: decision latency—the time between signal and action. As that gap wid
Nearly Half of Global C-Suites Plan U.S. Expansion Within 12 Months, as Supply Chain and Capital Access Drive Growth26.3.2026 14:00:00 CET | Press release
• 45% of C-level executives plan to establish a U.S. legal entity within the next 12 months; a further 27% say they will consider entry within two to three years • 65% cite supply chain or manufacturing efficiency as the primary driver for U.S. expansion • 88% identify federal and state tax reporting as the most burdensome area of U.S. compliance Nearly half (45%) of global C-suite leaders plan to establish a legal entity in the United States within the next 12 months, highlighting continued demand for access to the U.S. market. This finding from the latest research by CSC—the leading provider of global business administration and compliance solutions—demonstrates the U.S. continues to attract investment from around the world, even as companies face an increasingly complex regulatory landscape. CSC surveyed 300 C-level executives at large organizations headquartered in Europe, the U.K., Asia Pacific, and South America to examine global sentiment toward U.S. market entry, including expa
Lone Star Funds Completes Acquisition of Alliance Ground International26.3.2026 13:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has completed the acquisition of Alliance Ground International (“AGI”), a leading North American airport services provider. “We are excited to partner with the AGI management team to drive the business forward,” said Donald Quintin, Chief Executive Officer of Lone Star. “The company has a superior service offering and a track record of success across its integrated operations. We see opportunities to continue to invest in the business and its people to continue to grow its capabilities and ensure it remains best-in-class in delivering for the aviation industry.” “Today marks an important next step for AGI as we move forward in partnership with Lone Star,” said Jared Azcuy, Chief Executive Officer of AGI. “Our commitment to safety, reliability, and operational service excellence remains unchanged. This partnership strengthens our ability to deliver for our airline partners and reinforces that the
Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging26.3.2026 13:30:00 CET | Press release
The Phase 1 study of RLS-1496, the first human trial of a GPX4 (selective glutathione peroxidase 4) modulator, met its primary endpoint and also demonstrated a statistically significant relationship between target engagement and clinical improvement in psoriasis and atopic dermatitis RLS-1496 is a first-in-class disease-modifying mechanism targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases of aging A second study for RLS-1496 – a Phase 1b/2a study in actinic keratosis (precancerous skin lesions) – is underway in the United States, with completion expected later this year Rubedo CEO Frederick Beddingfield, III, MD, PhD, FAAD, to moderate panel on senescence and skin at the Dermatology Innovation Forum (DIF) during the American Academy of Dermatology (AAD) annual meeting on Thursday, March 26, at 1:05 pm MT in Denver Oral presentation of data accepted at the Society for Investigative Dermatology (SID) from May 13-16, 2026, in Chicago Rubedo L
GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe26.3.2026 13:30:00 CET | Press release
COMPASS is one of the largest public‑private partnerships under the European Union’s (EU) Innovative Health Initiative (IHI). The consortium aims to advance early detection and prediction of cardiotoxicity in cancer patients and cancer survivors. The initiative will leverage AI, advanced imaging, biomarkers, and integrated care pathways. GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI. Cardiovascular diseases are rising sharply among cancer patients and survivors, driven both by the increasing prevalence of pre‑existing cardiovascular conditions at diagnosis and by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
